期刊
CURRENT OPINION IN BIOTECHNOLOGY
卷 60, 期 -, 页码 146-152出版社
ELSEVIER SCI LTD
DOI: 10.1016/j.copbio.2019.01.013
关键词
-
资金
- National Institutes of Health [NS099158]
- Falk Medical Research Trust Catalyst Award
The blood-brain barrier (BBB) segregates the central nervous system from the systemic circulation. As such, the BBB not only prevents toxins and pathogens from entering the brain, but also limits the brain uptake of therapeutic molecules. However, under certain pathological conditions, the BBB is disrupted, allowing direct interaction between blood components and the diseased site. Moreover, techniques such as focused ultrasound can further disrupt the BBB in diseased regions. This review focuses on strategies that leverage such BBB disruption for delivering nanocarriers to the central nervous system (CNS). BBB disruption, as it relates to nanocarrier delivery, will be discussed in the context of acute pathologies such as stroke and traumatic brain injury, as well as chronic pathologies such as brain tumors, Alzheimer's disease, and Parkinson's disease. Key aspects of nanocarrier design as they relate to penetration and retention in the CNS are also highlighted.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据